Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38977 PHREESIA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-2275479 (State or Other J ...

Phreesia, Inc. (NYSE:PHR) Q3 2023 Earnings Conference Call December 8, 2022 5:00 PM ET Company Participants Balaji Gandhi - SVP, IR Chaim Indig - CEO & Co-Founder Randy Rasmussen - CFO Conference Call Participants Anne Samuel - JPMorgan Ryan Daniels - William Blair Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Stephanie Davis - SVB Securities Glen Santangelo - Jefferies Daniel Grosslight - Citi John Ransom - Raymond James Scott Schoenhaus - KeyBanc Joe Vruwink - Baird Ryan MacDonald - Nee ...

Revenue Growth - Total revenue increased 31% to $73.1 million for the three months ended October 31, 2022, compared to $55.9 million for the same period in 2021[130] - Total revenue increased 32% to $204.3 million for the nine months ended October 31, 2022, compared to $155.2 million for the same period in 2021[130] - Total revenue for the three months ended October 31, 2022, increased by $17.2 million, or 31%, to $73.1 million compared to $55.9 million for the same period in 2021[152] - Subscription and related services revenue rose by $8.6 million, or 35%, to $33.0 million for the three months ended October 31, 2022, driven by new healthcare services clients and expansion to existing clients[154] - Total revenue for the nine months ended October 31, 2022, increased by $49.1 million, or 32%, to $204.3 million compared to $155.2 million for the same period in 2021[153] Financial Losses - Net loss was $40.2 million for the three months ended October 31, 2022, compared to $36.3 million for the same period in 2021[130] - Adjusted EBITDA was negative $18.3 million for the three months ended October 31, 2022, compared to negative $17.6 million for the same period in 2021[130] - Adjusted EBITDA for the three months ended October 31, 2022, was a loss of $18.3 million, compared to a loss of $17.6 million for the same period in 2021[187] - Free cash flow was negative $27.5 million for the three months ended October 31, 2022, compared to negative $39.0 million for the same period in 2021[130] - Free cash flow for the three months ended October 31, 2022, was a negative $27.5 million, an improvement from negative $39.0 million in the same period of 2021[189] Cash and Cash Equivalents - Cash and cash equivalents as of October 31, 2022, were $209.6 million, a decrease of $104.2 million compared to January 31, 2022[130] - As of October 31, 2022, the company had cash and cash equivalents of $209.6 million, down from $313.8 million as of January 31, 2022[191] - The company believes that existing cash and cash equivalents, along with available financial resources, will be sufficient to meet its needs for at least the next 12 months[192] - The net decrease in cash and cash equivalents for the nine months ended October 31, 2022, was $104.2 million, contrasting with an increase of $181.6 million in the same period of 2021[197] Operating Activities - Net cash used in operating activities was $20.7 million for the three months ended October 31, 2022, compared to $24.5 million for the same period in 2021[130] - Cash used in operating activities for the nine months ended October 31, 2022, was $74.2 million, an increase from $36.7 million in the same period of 2021, reflecting higher employee compensation costs and outside services costs[199] - The increase in cash used in operating activities was driven by higher employee headcount and compensation costs, partially offset by increased cash received from customers due to higher revenues[200] Expenses - Cost of revenue (excluding depreciation and amortization) increased by $2.9 million, or 25%, to $14.6 million for the three months ended October 31, 2022, primarily due to higher employee compensation and benefits costs[156] - Research and development expense increased by $7.4 million, or 48%, to $22.7 million for the three months ended October 31, 2022, driven by higher compensation and increased headcount[166] - Sales and marketing expense rose by $4.6 million, or 14%, to $36.6 million for the three months ended October 31, 2022, primarily due to increased compensation and third-party costs[162] - General and administrative expense increased by $1.6 million, or 9%, to $19.6 million for the three months ended October 31, 2022, mainly due to higher compensation costs[170] - Payment processing expense increased by $8.7 million, or 30%, to $37.5 million for the nine months ended October 31, 2022, driven by an increase in patient payments processed[161] Depreciation and Amortization - Depreciation expense increased by $1.1 million to $4.9 million for the three months ended October 31, 2022, representing a 31% increase compared to $3.7 million for the same period in 2021[174] - For the nine months ended October 31, 2022, depreciation expense rose by $2.6 million to $13.4 million, a 25% increase from $10.7 million in the prior year[175] - Amortization expense increased by $0.3 million to $1.8 million for the three months ended October 31, 2022, reflecting a 20% increase from $1.5 million in the same period of 2021[176] Financing Activities - Net cash used in financing activities for the nine months ended October 31, 2022, was $10.4 million, compared to a net cash inflow of $242.9 million in the same period of 2021, which included $245.8 million from a common stock offering[203][204] - The Third SVB Facility allows for borrowings up to $100.0 million, with an interest rate of 5.75% as of October 31, 2022, and no outstanding balance[194] - The company was in compliance with all covenants related to the Third SVB Facility as of October 31, 2022[196] Market Risks and Accounting Policies - The company continues to be exposed to market risks, including interest rate and foreign exchange risks, with no significant changes reported during the nine months ended October 31, 2022[210] - There were no significant changes in critical accounting policies and estimates during the nine months ended October 31, 2022[208] - The primary sources of cash from operating activities include cash received from customers and interest earned on money market mutual funds[198]

Financial Data and Key Metrics Changes - Revenue for Q2 2023 was $68 million, representing a 33% year-over-year increase, marking the sixth consecutive quarter of over 30% revenue growth [12][11] - Health care services revenue, which includes subscription and related services and payment processing revenue, increased by 29% year-over-year [13] - Adjusted EBITDA outlook for fiscal 2023 was raised to a range of negative $109 million to negative $106 million, improved from the previous range of negative $126 million to negative $122 million [17] Business Line Data and Key Metrics Changes - The average number of health care services clients reached 2,776, with an addition of 250 clients sequentially, achieving a 40% year-over-year growth [12] - Payment processing revenue grew by 20% year-over-year, following a 38% growth in the same quarter last year [14] - Life Sciences revenue saw a significant increase of 46% year-over-year, building on a 95% growth from the previous year [15] Market Data and Key Metrics Changes - Phreesia now impacts over 10% of patient visits in the U.S. daily, indicating a strong market presence [15] - The company expects to end fiscal 2023 with cash and cash equivalents between $165 million and $170 million, supporting its growth plans [18] Company Strategy and Development Direction - The company is focused on maintaining a best-in-class product offering, expanding relationships with existing clients, and growing its network with new clients [18] - Investments in product development and client success are seen as critical to driving future growth and shareholder value [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving adjusted EBITDA profitability by fiscal 2025, supported by strong performance and effective cost management [17][33] - There is a pragmatic approach to utilization expectations, with no anticipated significant increases in the second half of the year [54] Other Important Information - The company has not observed any significant trends in rising patient self-pay balances affecting its payment processing outlook [56] - Management emphasized the importance of building trust with clients and providing value to drive expansion within existing accounts [81] Q&A Session Summary Question: Insights on EBITDA guidance raise - Management highlighted a focus on smart spending and careful evaluation of expenses as key factors in the improved EBITDA outlook [21][22] Question: Life Sciences business performance - Management noted that investments in network growth and product development have significantly contributed to the strong performance in Life Sciences [23] Question: Visibility on digital advertising and Life Sciences growth - Management indicated decent visibility for the fiscal year but noted January as a month with less visibility due to client fiscal year-end contracts [27][29] Question: Cash flow guidance and balance sheet confidence - Management confirmed confidence in cash balances and the ability to execute on the fiscal 2025 plan without any borrowings [33][34] Question: Average revenue per client trends - Management clarified that the decline in average revenue per client is primarily due to the growth in the payments business, while subscription revenue per client has remained stable [49][50] Question: Utilization expectations - Management does not expect a significant increase in utilization in the second half of the year, based on current data and provider feedback [54][76] Question: Competition and market dynamics - Management acknowledged ongoing competition but emphasized the complexity of their offerings and the value they provide to clients [61][62] Question: Payment processing ramp-up for new clients - Management explained that there is typically a ramp-up period of three to four months for new clients to fully transition to their payment solutions [69] Question: Client retention and health care services - Management reported consistent client retention rates, with no significant changes observed in the macro environment affecting retention [117][118]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or othe ...

Financial Data and Key Metrics Changes - The average healthcare services clients increased by 33% year-over-year [10] - Revenue outlook for the year is maintained at $271 million to $275 million, implying a growth of 27% to 29% year-over-year [11] - Adjusted EBITDA outlook improved to a range of negative $126 million to negative $122 million, up from a prior outlook of negative $154 million to negative $149 million [13] Business Line Data and Key Metrics Changes - Life sciences growth was up 51% year-over-year, although revenue decreased slightly by $563,000 sequentially from Q4 [12] Market Data and Key Metrics Changes - Patient utilization trends were slightly below expectations, which may persist throughout the year [11] Company Strategy and Development Direction - The company focuses on building great products and expanding its client base, emphasizing a "land and expand" strategy [21][24] - Management is committed to addressing social determinants of health, aiming to empower providers rather than monetizing these services [33] Management's Comments on Operating Environment and Future Outlook - Management noted a mixture of COVID-related issues affecting both staff and patient attendance, impacting overall patient utilization trends [30] - The company is confident in its ability to achieve profitability by fiscal 2025, with expected revenue growth at a CAGR of 28% and expenses growing at 10% to 11% [77] Other Important Information - The company has maintained a consistent subscription revenue per provider client at $11,500 for several quarters [21] - The current cash balance and line of credit are deemed sufficient to finance the company's plans to achieve its 2025 targets [77] Q&A Session Summary Question: Dynamics around revenue per provider client and decline - Management explained that the decline is due to a "land and expand" strategy where new clients initially generate lower revenue [21] Question: Update on patient utilization trends - Management indicated that trends are influenced by a combination of COVID impacts and staffing issues [30] Question: Update on social determinants of health offering - Management emphasized the importance of addressing social determinants without monetizing them, focusing on empowering providers [33] Question: Insights on subscription revenue per client - Management noted low churn rates and success in upselling and cross-selling, indicating a strong customer retention strategy [64] Question: Pipeline for enterprise clients - Management stated that the go-to-market strategy remains consistent, focusing on delivering value and continuous engagement with clients [104] Question: Changes in marketing and campaign scrutiny - Management acknowledged increased scrutiny on marketing effectiveness and a shift away from traditional advertising methods [94]

Investor Presentation June 2022 DISCLAIMER This presentation includes express or implied statements that are not historical facts and are considered forward- looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial informa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or oth ...

Phreesia, Inc. (NYSE:PHR) Q4 2022 Earnings Conference Call March 30, 2022 5:00 PM ET Company Participants Balaji Gandhi - SVP, IR Chaim Indig - CEO and Co-Founder Randy Rasmussen - CFO Conference Call Participants Anne Samuel - JPMorgan Thomas Kelliher - RBC Capital Markets Jessica Tassan - Piper Sandler Richard Close - Canaccord Genuity Daniel Grosslight - Citigroup John Ransom - Raymond James Joy Zhang - SVB Leerink Glen Santangelo - Jefferies Ryan MacDonald - Needham & Company Joe Vruwink - Robert ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38977 PHREESIA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-2275479 (State or Other J ...